TrialSignal
Clinical trial intelligence report
Phase 3b, Randomized, Open-label, Active-controlled Trial Evaluating the Efficacy and Safety of Oral Vadadustat Once Daily (QD) and Three Times Weekly (TIW) for the Maintenance Treatment of Anemia in Hemodialysis Subjects Converting From Erythropoiesis-Stimulating Agents (ESAs)
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jun 20, 2026
NCT ID
NCT04313153
Status
COMPLETED
Phase
Phase 3b
Sponsor
Akebia Therapeutics
Executive brief
Investment-Ready Snapshot
This clinical trial evaluated the efficacy and safety of vadadustat, an oral medication, compared to darbepoetin alfa, an established erythropoiesis-stimulating agent (ESA), for maintaining hemoglobin levels in hemodialysis patients transitioning from ESA therapy. The study involved 319 participants and was conducted by Akebia Therapeutics in collaboration with Otsuka Pharmaceutical Development & Commercialization.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT04313153
Indication
Anemia
Modality
small molecule
Target
Anemia in Hemodialysis Patients
Intervention
Vadadustat, Darbepoetin alfa
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.